Abstract 1247P
Background
Volatile organic compounds (VOCs) are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. In this study, we aimed to investigate the potential of VOCs analysis as a non-invasive method for early detection of EGFR mutation.
Methods
We collected breath samples from 114 EGFR wild-type lung adenocarcinoma patients and 132 EGFR mutant lung adenocarcinoma patients and analyzed them using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry (HPPl-TOFMS) to detect VOCs. A detection model for EGFR mutation based on VOC analysis was established using the eXtreme Gradient Boosting (XGB) algorithm. For building the EGFR mutation detection model, all the samples were randomly split into a training set, validation set, and test set with a ratio of 5:2:3.
Results
The top ten VOC ions which were significantly different between the EGFR mutant lung adenocarcinoma patients and patients without EGFR mutation were displayed in the table (P < 0.05). The discrimination power of each VOC was relatively limited. Among them, 2-Ethyl-4,5-dimethylthiazole had the highest accuracy with an area under the receiver operating characteristic curve (AUC) of 0.829 (95%CI: 0.744-0.974). With the combination of these 10 VOC ions, the model performs well. The AUC for the combination model was 0.895 (95% CI: 0.810-0.980) in the validation cohort, while the AUC in the test set was 0.849 (95% CI: 0.769-0.930), indicating good diagnostic accuracy, with sensitivity and specificity of 70.7% (95% CI: 56.6%, 84.4%) and 71.4% (95% CI: 56.2%, 86.6%). Table: 1247P
The top 10 VOC ions related to EGFR mutation in lung adenocarcinoma
Chemicals | Peak area | P-value | |
EGFR mut | RGFR wild | ||
Cyclohexanone oxime | 242.6±103.4 | 139.1±234.1 | <0.001 |
Dimethoxybenzene | 522.7±1730.2 | 200.0±256.6 | 0.017 |
Tert-Butyl methyl ether | 667.5±1655.3 | 278.4±302.0 | 0.006 |
2-Ethyl-4,5-dimethylthiazole | 659.0±1762.2 | 329.7±730.8 | 0.039 |
Trimethylbenzene | 375.1±617.7 | 202.9±185.6 | <0.001 |
Salicylamide | 310.6±332.9 | 203.0±187.3 | <0.001 |
p-cymene/Cinnamyl alcohol | 300.5±1002.5 | 123.5±130.7 | 0.038 |
L-serine/D-serine | 706.2±515.0 | 359.9±318.0 | <0.001 |
1-Propanethiol | 2005.3±1609.7 | 1419.7±1673.0 | 0.002 |
4-Methylanisole/2-Methylanisole | 402.1±314.4 | 180.1±220.1 | <0.001 |
Conclusions
Our study suggested that VOCs analysis might be useful as non-invasive methods for early detection of EGFR mutations in lung adenocarcinoma. Further studies are needed to validate the accuracy of our model.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Chinese National Natural Science Foundation Project; China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14